PCH cancer patients must go to Charlottetown for treatment until July 10, says Health P.E.I.
The oncology department at Summerside's Prince County Hospital is short-staffed, said Health P.E.I., so patients receiving chemotherapy will be treated at Queen Elizabeth Hospital from now until July 10.
The agency said in a statement that no treatment schedules have been interrupted because of the shortage, and that patients who require transportation and other support can pay upfront and apply to PCH for reimbursement.
Heather Mulligan, senior manager of advocacy for Atlantic Canada with the Canadian Cancer Society, said disruptions like this can cause an extra burden on patients and their families.
With lengthy travel to appointments becoming more common across the country, she said things like gas, food and sometimes overnight accommodations can add up.
"Any amount of travel puts a significant burden, not only on our patients, but [on] their loved ones, their caregivers who are accompanying them for their care," Mulligan said.
"Whether it be for a couple of days, couple of weeks, couple of months, [it] is quite a significant burden, not only in terms of the emotional toll that it takes on a patient, but also the financial impact that it has on a family."
Patients who need to see a medical oncologist — a doctor who specializes in diagnosing cancer and prescribing treatments — will also have to travel to the Charlottetown hospital "until the end of August (or sooner)," Health P.E.I. said.
There are two-full time oncologists at the QEH who also provide part-time coverage at Prince County Hospital.
There will be periods of time when only one of those oncologists is available, so the service will have to be provided in Charlottetown.
"To support this temporary operational shift, some nursing staff from PCH will be reassigned to QEH. Reassignment of nursing staff is guided by the [P.E.I. Nurses Union] collective agreement, which includes provisions for travel pay and compensation," Health P.E.I. said in a statement.
"In mid-September, a third full-time medical oncologist will join the team at the QEH Cancer Treatment Centre, increasing the complement of specialists and enhancing service capacity."
Unexpected side effects
The cancer society is calling on the P.E.I. government to offer a refundable tax credit for Islanders who are providing practical support to loved ones undergoing treatment.
Mulligan said a recent study the organization conducted in conjunction with Statistics Canada showed the average cancer patient and their family will shoulder more than $30,000 in out-of-pocket expenses over the course of their treatment.
That can lead to unfortunate consequences, she said.
"For some patients, it [means] taking on debt, and that's the number-one side effect of cancer that no one expects," Mulligan said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
an hour ago
- CBC
Smilezones make pediatric spaces less scary for kids at this P.E.I. hospital
Prince Edward Island now has its first Smilezone spaces at Queen Elizabeth Hospital in Charlottetown. The areas are designed to make the hospital more welcoming for pediatric patients and their families. Staff say they're already having an impact. CBC's Sheehan Desjardins has the story.
CTV News
8 hours ago
- CTV News
‘Mole Mobile' stops in North Bay to offer skin cancer screening
A mobile melanoma cancer clinic pulled into North Bay on Thursday morning and will be back in action there again Friday. A mobile melanoma cancer clinic pulled into North Bay on Thursday morning and will be back in action there again Friday, where a doctor screens people for skin cancer. 'Mole Mobile' is visiting major Canadian cities with long wait times to see a dermatologist and underserved communities to help speed up diagnosis. Mole main A mobile melanoma cancer clinic pulled into North Bay on Thursday morning and will be back in action there again Friday, where a doctor screens people for skin cancer. (Eric Taschner/CTV News) Dermatologist Dr. Michael Connolly is helping Melanoma Canada by screening patients by checking for melanoma inside the mobile unit. 'This type of service should be more available to patients,' Connolly said. Melanoma and skin cancer rates have been increasing across the globe. Incidence rates for new melanoma cases have been rising on average by 1.4 per cent each year over the last 10 years. When examining patients, Connolly examines what he describes as the 'ABCs' of melanoma -- asymmetry, border, colour, diametre and evolving. These characteristics help health-care professionals recognize suspicious moles or lesions that may warrant further examination. Common type of cancer 'We check not only for melanoma, but we check for non-melanoma skin cancers, too,' Connolly said. 'Like basal cells, squamous cells and for pre-cancerous lesions.' Skin cancers are the most common type of cancer diagnosed in men older than 49 and are among the most common cancers diagnosed in youth and young adults. If detected early, melanoma and skin cancers are largely treatable. Colleen Piekarski Colleen Piekarski knows the importance of getting checked all too well. In 2013, she discovered a bump on her scalp, which turned out to be Stage 3 melanoma. (Eric Taschner/CTV News) Colleen Piekarski knows the importance of getting checked all too well. In 2013, she discovered a bump on her scalp, which turned out to be Stage 3 melanoma. Piekarski's biopsy results were serious. She had immediate head and neck surgery, where a two-inch circle of her scalp and 14 lymph nodes were removed. She then underwent intense rounds of radiation. She started a drug trial, which was unsuccessful, and she was urgently switched to another trial at Princess Margaret Hospital. After eight weeks of initial treatment, the response was going well. So, she continued to receive treatment every two weeks in Toronto for the next six months before she was able to ring the bell in 2015. Ten years later, she's cancer-free but still follows recommendations to wear a wide-brimmed hat and sunscreen when outdoors. 'It's not a little skin cancer on the surface of your skin. It is deep and it can get into your lymph nodes and into your bloodstream and it can move,' she said. Mole Mobile 'Mole Mobile' is visiting major Canadian cities with long wait times to see a dermatologist and underserved communities to help speed up diagnosis. (Eric Taschner/CTV News) She, along with her son Christopher, have organized walks for melanoma awareness in North Bay. She said she's happy knowing others are getting screened. Piekarski plans to even go to the Mole Mobile with her daughter for a quick followup. 'I think it's super important,' she said. During Melanoma Canada's last Mole Mobile tour in Ontario, more than 2,200 people were screened at 30 stops. Among them, dermatologists identified 56 potential melanomas, 148 suspected basal cell carcinomas and 36 possible cutaneous squamous cell carcinomas. The Mole Mobile will be set up Friday at Sunset Park (across from Perreault's Prime Time Ice Fishing) from 10 a.m. until 4 p.m. in North Bay. On Saturday, it will be in Sudbury at Bell Park, in the York Street South Parking Lot, from 10 a.m. until 4 p.m. On Sunday, it will be in Parry Sound at Canadian Tire, 30 Pine Dr., from 10 a.m. until 4 p.m. No appointment is needed and the free skin check will be performed by a certified dermatologist.
Globe and Mail
a day ago
- Globe and Mail
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025
SEATTLE, July 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ('Perspective' or the 'Company') (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company's [ 212 Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2025 taking place October 17 to 21, 2025 in Berlin, Germany. ESMO plans to release further details for regular abstracts on October 13, 2025. About [ 212 Pb]VMT-α-NET Perspective designed [ 212 Pb]VMT-α-NET to target and deliver 212 Pb to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study ( identifier NCT05636618) of [ 212 Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received a prior RPT. Interim update with a data cut-off date of April 30, 2025 were reported in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2025. Cohort 2 was reopened in August 2024. During 2H 2025, some of the 33 additional patients enrolled after the cohort reopened and through April 30, 2025 will have had the opportunity for at least 32 weeks of follow-up after their initial doses, sufficient time to receive at least one scan after their full treatment (up to four doses every eight weeks), if they receive all four doses of treatment per protocol. About Perspective Therapeutics, Inc. Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212 Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01), neuroendocrine tumor (VMT-α-NET) and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary 212 Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations. For more information, please visit the Company's website at Safe Harbor Statement This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the Company's plans and the expected timing for the release of additional data from its clinical programs; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212 Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that complementary imaging diagnostics that incorporate certain targeting moieties provide the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary 212 Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact. The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
